Background: For quick detection or exclusion of neonatal early-onset bacterial infection (EOBI) or late-onset bacterial infection (LOBI), interleukin (IL)-6 is used. Its clinical use is sometimes limited due to prolonged recall times. Therefore, an IL-6 bedside test was established. Objective: To compare the diagnostic value of plasma IL-6 and an IL-6 bedside test at the time of clinical suspicion in the course of EOBI and LOBI. Methods: Eighteen term (mean gestational age 40.2 weeks, SD 1.3) and 88 preterm (mean gestational age 30.1 weeks, SD 4.2) neonates with clinical and serological signs of bacterial infection were analysed. Eight had an EOBI, and 24 had a LOBI, of whom 13 were blood culture positive. Twelve term and 62 preterm neonates with risk factors but without proven EOBI/LOBI served as a non-infected group. Results: At the time of clinical suspicion, the sensitivity of the IL-6 bedside test in comparison to plasma IL-6 was 69 versus 75% (p = 0.7744, McNemar’s test), and specificity was 77 versus 81% (p = 0.6476, McNemar’s test; cutoff level 50 ng/l). For LOBI, both the sensitivity (75%) and specificity (82%) of the bedside test exceeded values calculated for EOBI (sensitivity 50%, specificity 75%). Conclusion: No significant difference between the bedside and established plasma IL-6 test was detected for LOBI. For detection of EOBI, the bedside test was not sensitive enough. Larger studies are needed to verify our findings before IL-6 bedside tests can be recommended routinely.

Keywords:
Interleukin-6, Bedside test, Preterm infants, Term infants, Infants, Sepsis, Neonate, Bacterial infection
1.
Anderson-Berry A, Brinton B, Lyden E, Faix RG: Risk factors associated with development of persistent coagulase-negative staphylococci bacteremia in the neonate and associated short-term and discharge morbidities. Neonatology 2011;99:23–31.
2.
Orlikowsky TW, Neunhoeffer F, Goelz R, Eichner M, Henkel C, Zwirner M, Poets CF: Evaluation of IL-8-concentrations in plasma and lysed EDTA-blood in healthy neonates and those with suspected early onset bacterial infection. Pediatr Res 2004;56:804–809.
3.
Geffers C, Baerwolff S, Schwab F, Gastmeier P: Incidence of healthcare-associated infections in high-risk neonates: results from the German surveillance system for very-low-birthweight infants. J Hosp Infect 2008;68:214–221.
4.
Saugstad OD: Reducing global neonatal mortality is possible. Neonatology 2011;99:250–257.
5.
van den Hoogen A, Gerards LJ, Verboon-Maciolek MA, Fleer A, Krediet TG: Long-term trends in the epidemiology of neonatal sepsis and antibiotic susceptibility of causative agents. Neonatology 2010;97:22–28.
6.
Stocker M, Fontana M, El Helou S, Wegscheider K, Berger TM: Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. Neonatology 2010;97:165–174.
7.
Kuster H, Weiss M, Willeitner AE, Detlefsen S, Jeremias I, Zbojan J, Geiger R, Lipowsky G, Simbruner G: Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation. Lancet 1998;352:1271–1277.
8.
van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A: Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990;76:2520–2526.
9.
Fong Y, Moldawer LL, Marano M, Wei H, Tatter SB, Clarick RH, Santhanam U, Sherris D, May LT, Sehgal PB, et al: Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man. J Immunol 1989;142:2321–2324.
10.
Benitz WE, Han MY, Madan A, Ramachandra P: Serial serum C-reactive protein levels in the diagnosis of neonatal infection. Pediatrics 1998;102:E41.
11.
Mathers NJ, Pohlandt F: Diagnostic audit of C-reactive protein in neonatal infection. Eur J Pediatr 1987;146:147–151.
12.
Dollner H, Vatten L, Austgulen R: Early diagnostic markers for neonatal sepsis: comparing C-reactive protein, interleukin-6, soluble tumour necrosis factor receptors and soluble adhesion molecules. J Clin Epidemiol 2001; 54:1251–1257.
13.
Laborada G, Rego M, Jain A, Guliano M, Stavola J, Ballabh P, Krauss AN, Auld PA, Nesin M: Diagnostic value of cytokines and C-reactive protein in the first 24 hours of neonatal sepsis. Am J Perinatol 2003;20:491–501.
14.
Doellner H, Arntzen KJ, Haereid PE, Aag S, Austgulen R: Interleukin-6 concentrations in neonates evaluated for sepsis. J Pediatr 1998;132:295–299.
15.
Ng PC, Cheng SH, Chui KM, Fok TF, Wong MY, Wong W, Wong RP, Cheung KL: Diagnosis of late onset neonatal sepsis with cytokines, adhesion molecule, and C-reactive protein in preterm very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 1997;77:F221–F227.
16.
Schultz C, Rott C, Temming P, Schlenke P, Moller JC, Bucsky P: Enhanced interleukin-6 and interleukin-8 synthesis in term and preterm infants. Pediatr Res 2002;51:317–322.
17.
Schultz C, Temming P, Bucsky P, Gopel W, Strunk T, Hartel C: Immature anti-inflammatory response in neonates. Clin Exp Immunol 2004;135:130–136.
18.
Franz AR, Sieber S, Pohlandt F, Kron M, Steinbach G: Whole blood interleukin 8 and plasma interleukin 8 levels in newborn infants with suspected bacterial infection. Acta Paediatr 2004;93:648–653.
19.
Hengst JM: The role of C-reactive protein in the evaluation and management of infants with suspected sepsis. Adv Neonatal Care 2003;3:3–13.
20.
Milenia Biotec GmbH: Lateral Flow Immunoassay for the quantitative measurement of human interleukin-6 (IL-6) in whole blood. 2010. http://www.milenia-biotec.de/fileadmin/user_upload/arbeitsanleitungen/schnelltests/MQL6B/MQL6BN_J.pdf.
21.
Prinsen JH, Baranski E, Posch H, Tober K, Gerstmeyer A: Interleukin-6 as diagnostic marker for neonatal sepsis: determination of Access IL-6 cutoff for newborns. Clin Lab 2008;54:179–183.
22.
Faust K, Göpel W, Herting E, Härtel C: Sepsis bei Frühgeborenen mit einem sehr niedrigen Geburtsgewicht. Chemother J 2011;20:1–8.
23.
Buck C, Bundschu J, Gallati H, Bartmann P, Pohlandt F: Interleukin-6: a sensitive parameter for the early diagnosis of neonatal bacterial infection. Pediatrics 1994;93:54–58.
24.
Caldas JP, Marba ST, Blotta MH, Calil R, Morais SS, Oliveira RT: Accuracy of white blood cell count, C-reactive protein, interleukin-6 and tumor necrosis factor alpha for diagnosing late neonatal sepsis. J Pediatr (Rio J) 2008;84:536–542.
25.
Ottolini MC, Lundgren K, Mirkinson LJ, Cason S, Ottolini MG: Utility of complete blood count and blood culture screening to diagnose neonatal sepsis in the asymptomatic at risk newborn. Pediatr Infect Dis J 2003;22:430–434.
26.
Dembinski J, Behrendt D, Martini R, Heep A, Bartmann P: Modulation of pro- and anti-inflammatory cytokine production in very preterm infants. Cytokine 2003;21:200–206.
27.
Panero A, Pacifico L, Rossi N, Mancuso G, Stegagno M, Chiesa C: Interleukin 6 in neonates with early and late onset infection. Pediatr Infect Dis J 1997;16:370–375.
28.
Chiesa C, Panero A, Osborn JF, Simonetti AF, Pacifico L: Diagnosis of neonatal sepsis: a clinical and laboratory challenge. Clin Chem 2004;50:279–287.
29.
Franz AR, Steinbach G, Kron M, Pohlandt F: Reduction of unnecessary antibiotic therapy in newborn infants using interleukin-8 and C-reactive protein as markers of bacterial infections. Pediatrics 1999;104:447–453.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.